Skip to main content

Table 1 Epidemiological input data used in the model a

From: Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe

Gender Cancer sites (ICD 10 code) Expected number of new cases, irrespective of HPV status HPV prevalence by site (%) Expected number of new cases attributable to HPV Prevalence of HPV 16/18 in HPV-positive cancers (%) Expected number of new cancer cases attributable to HPV 16/18 Prevalence of HPV 6/11 in HPV-positive warts (%) Expected number of new cancer cases attributable to HPV 6/11
Male Head and neckb 67,354   14,098   12,707   
  Anus (C21) 2,162 84.2 1,821 87.1/6.2 1,699   
  Penis (C60) 3,178 46.7 1,484 60.2/13.4 1,091   
  Genital warts 380,961      85.5 325,722
Female Cervical cancer 30,517 - - 59.2/17.0 23,254   
  Vaginal 1,869 69.9 1,306 76.8/10.9 1,146   
  Vulvar 7,384 40.4 2,983 79.7/10.9 2,702   
  Anus (C21) 3,727 84.3 3,141 87.1/6.2 2,929   
  Head and neck 13,448   2,715   2,531   
  Genital warts 337,963      85.5 288,959
  1. HPV, human papillomavirus.
  2. aIn total 26 countries were considered in the analysis for incidence estimates, i.e. all European Union countries (except Greece, Hungary, Luxembourg, and Romania). Three countries outside the European Union were included (Iceland, Norway and Switzerland).
  3. bincludes several ICD 10 codes related sites (i.e., tongue, gum of the mouth, floor of the mouth, palate, tonsil, piriform sinus), hypopharynx and larynx sites.